



Market Announcement

20 January 2022

HeraMed Limited (ASX: HMD) – Suspension from Quotation

Description

The securities of HeraMed Limited ('HMD') will be suspended from quotation immediately under Listing Rule 17.2, at the request of HMD, pending the release of an announcement regarding an Australian based commercial licence agreement for the roll-out of the HeraCARE solution.

Issued by

Raj Logarajah
Adviser, Listings Compliance (Perth)

For personal use only

ASX ANNOUNCEMENT**20 January 2022**

ASX Announcements Office
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000

Via Email: tradinghaltspert@asx.com.au

Dear Barbara

REQUEST FOR VOLUNTARY SUSPENSION – ASX:HMD

Pursuant to Listing Rule 17.2, HeraMED Limited (**HMD** or the **Company**) requests a voluntary suspension be applied to the Company's securities and set out below are the details of that request.

Further to HMD's request for trading halt on Tuesday, 18 January 2022, the Company is not in a position to make an announcement at this time, and requests a voluntary suspension, pending an announcement by the Company regarding an Australian based commercial licence agreement for the roll-out of the HeraCARE solution.

The Company requests that the suspension remain in place until the release of an announcement regarding the commercial agreement, which is expected to be Friday, 21 January 2022.

The company confirms that it is not aware of any reason why this voluntary suspension should not be granted.

This announcement has been authorised by the Board of HMD.

Jonathan Hart
Company Secretary

-ENDS-